« Back to Record
Citation APA

Tijtgat, J., Geeraerts, X., Boisson, A., Stevens, L., Vounckx, M., Dirven, I., Schwarze, J. K., Raeymaeckers, S., Forsyth, R., Van Riet, I., Tuyaerts, S., Willard-Gallo, K., & Neyns, B. (2024). Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for ImmunoTherapy of Cancer, 12(1), e008148. doi:10.1136/jitc-2023-008148


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/371977

Tijtgat, J., Geeraerts, X., Boisson, A., Stevens, L., Vounckx, M., Dirven, I., Schwarze, J. K., Raeymaeckers, S., Forsyth, R., Van Riet, I., Tuyaerts, S., Willard-Gallo, K., & Neyns, B. (2024). Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for ImmunoTherapy of Cancer, 12(1), e008148. doi:10.1136/jitc-2023-008148